
    
      Objectives:

      Primary objective:

      Evaluate bioequivalence between a new paediatric formulation of vigabatrin (VGB-ST) and
      Sabril granules for oral administration.

      Secondary objective:

        -  Define pharmacokinetic parameters of the new paediatric formulation soluble tablets of
           vigabatrin (VGB-ST)

        -  Assess the safety of the new formulation of soluble tablets VGB-ST versus Sabril
    
  